U.S.: Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact

Hepatitis C virus treatment is often restricted in Medicaid [in Canada this would be PharmaCare] patients. This analysis evaluates the clinical and cost impacts of treating all Medicaid patients versus the current status quo. The objectives of this study were to estimate change in chronic hepatitis C virus (HCV) disease and the economic burden associated with comprehensive treatment of the chronic HCV–infected Medicaid population. As has long been pred